AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist
- First Posted Date
- 2010-09-09
- Last Posted Date
- 2014-04-07
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 323
- Registration Number
- NCT01197755
- Locations
- 🇬🇧
Research Site, Wirral, United Kingdom
Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Not Responding.
Phase 3
Completed
- Conditions
- Rheumatoid Arthritis
- Interventions
- First Posted Date
- 2010-09-09
- Last Posted Date
- 2014-04-07
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 923
- Registration Number
- NCT01197521
- Locations
- 🇬🇧
Research Site, Wirral, United Kingdom
Investigation of Efficacy, Safety and Tolerability of Once and Twice Daily Doses of AZD1981 in Asthmatic Patients
- First Posted Date
- 2010-09-09
- Last Posted Date
- 2013-11-06
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1144
- Registration Number
- NCT01197794
- Locations
- 🇺🇦
Research Site, Zaporozhye, Ukraine
Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Disease Modifying Anti-rheumatic Drug (DMARD) But Not Responding.
Phase 3
Completed
- Conditions
- Rheumatoid Arthritis
- Interventions
- First Posted Date
- 2010-09-09
- Last Posted Date
- 2014-04-17
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 913
- Registration Number
- NCT01197534
- Locations
- 🇬🇧
Research Site, Swindon, United Kingdom
A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder.
- First Posted Date
- 2010-09-09
- Last Posted Date
- 2014-04-11
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 696
- Registration Number
- NCT01197508
- Locations
- 🇺🇦
Research Site, Vinnytsya, Ukraine
Single Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD4451
- First Posted Date
- 2010-09-08
- Last Posted Date
- 2011-08-01
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 63
- Registration Number
- NCT01196676
- Locations
- 🇺🇸
Research Site, Overland Park, Kansas, United States
Pharmacokinetics in Adolescents
Phase 1
Completed
- Conditions
- Asthma
- Interventions
- Drug: AZD1981 100 mg twice daily for 61/2 days
- First Posted Date
- 2010-09-08
- Last Posted Date
- 2011-03-07
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 21
- Registration Number
- NCT01196689
- Locations
- 🇸🇪
Research Site, Uppsala, Sweden
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
Phase 3
Completed
- Conditions
- Type 2 Diabetes
- Interventions
- First Posted Date
- 2010-09-06
- Last Posted Date
- 2016-12-29
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 2245
- Registration Number
- NCT01195662
- Locations
- 🇺🇸
Abington Memorial Hos/Feasterville Family Health Care Center, Feasterville, Pennsylvania, United States
🇺🇸The Clinical Trial Center, Llc, Jenkintown, Pennsylvania, United States
🇺🇸Research Across America, Reading, Pennsylvania, United States
Evaluation of Histamine H3 Receptor Radioligand [11C]AZ12807110 and Histamine H3 Receptor Occupancy of AZD5213 After Oral Administration
Phase 1
Completed
- Conditions
- Brain Distribution of [11C]AZ12807110 and AZD5213
- Interventions
- Other: [11C]AZ12807110
- First Posted Date
- 2010-09-03
- Last Posted Date
- 2015-01-28
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 13
- Registration Number
- NCT01194986
- Locations
- 🇸🇪
Research Site, Uppsala, Sweden
Preliminary Anti-tumour Activity of mTor Kinase Inhibitor in Advanced Tumours
- First Posted Date
- 2010-09-02
- Last Posted Date
- 2011-05-16
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 63
- Registration Number
- NCT01194193